'Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing' - DOJ
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals has agreed to pay $450 million to settle allegations of violating the False Claims Act. The settlement resolves claims that Teva engaged in kickback schemes related to copayments and price fixing.
October 10, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Teva Pharmaceuticals has agreed to a $450 million settlement with the DOJ over allegations of kickbacks and price fixing, which could impact its financials and reputation.
The $450 million settlement is a significant financial outlay for Teva, which may affect its short-term financial performance. Additionally, the allegations of kickbacks and price fixing could harm its reputation, potentially impacting investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100